Eli Lilly LLY · NYSE
$1,256.32 +0.38% (+$4.71)
Summary
73 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 52% a year over the last 3 years.
- Out of every 100 USD of revenue, 34 USD is left as net profit.
- It earns 27 USD a year on every 100 USD of invested capital.
- It has raised its dividend 11 years in a row and pays out only 24% of profit.
What to watch
- The share price is above the Bulios Fair Price.
- For every 100 USD of shareholders' equity it carries 162 USD of debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 44.1 USD for 1 USD of yearly profit. Over the last five years it was 63.2 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 32% a year. For the next fiscal year analysts expect revenue to grow by 36%. Earnings per share grew by 52% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 16 USD
- Research and development 18 USD
- Sales and administration 22 USD
- Taxes and other 10 USD
- Net profit 34 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 34 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.53%
- Paid out of profit
- 24%
- Raised in a row
- 11 years
You receive $6.69 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 33
- Hold 9
- Sell 3
Today's price within the analysts' price targets
The average target of $1,343 is 7.1% above today's price. 73% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 94%
- Collaboration and Other Revenue 6.5%
By region
- UNITED STATES 67%
- Europe 18%
- Non-US 9.3%
- JAPAN 3.3%
- CHINA 3.0%
Product brings in 94% of revenue.
Segments in detail